| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Heart Failure | 21 | 2026 | 965 | 4.690 |
Why?
|
| Percutaneous Coronary Intervention | 12 | 2026 | 226 | 4.050 |
Why?
|
| Randomized Controlled Trials as Topic | 16 | 2026 | 809 | 3.400 |
Why?
|
| Atrial Fibrillation | 17 | 2025 | 884 | 3.080 |
Why?
|
| Cardiovascular Diseases | 14 | 2026 | 872 | 2.500 |
Why?
|
| Stroke | 15 | 2025 | 1221 | 2.460 |
Why?
|
| Coronary Artery Disease | 6 | 2025 | 326 | 2.420 |
Why?
|
| Cardiac Surgical Procedures | 6 | 2023 | 272 | 2.210 |
Why?
|
| Pharmacovigilance | 4 | 2024 | 15 | 2.060 |
Why?
|
| Myocardial Infarction | 9 | 2023 | 921 | 2.040 |
Why?
|
| Diabetes Mellitus, Type 2 | 12 | 2026 | 733 | 1.960 |
Why?
|
| Acute Coronary Syndrome | 3 | 2024 | 254 | 1.900 |
Why?
|
| Non-ST Elevated Myocardial Infarction | 3 | 2026 | 33 | 1.870 |
Why?
|
| Myocardial Revascularization | 2 | 2026 | 78 | 1.700 |
Why?
|
| Humans | 110 | 2026 | 65654 | 1.680 |
Why?
|
| Renal Insufficiency, Chronic | 6 | 2026 | 146 | 1.650 |
Why?
|
| ST Elevation Myocardial Infarction | 6 | 2025 | 96 | 1.630 |
Why?
|
| Coronary Artery Bypass | 4 | 2025 | 292 | 1.590 |
Why?
|
| Catheter Ablation | 6 | 2025 | 160 | 1.580 |
Why?
|
| Kidney Diseases | 3 | 2025 | 178 | 1.580 |
Why?
|
| Endovascular Procedures | 3 | 2025 | 631 | 1.550 |
Why?
|
| Heart Arrest | 4 | 2023 | 177 | 1.540 |
Why?
|
| Hypoglycemic Agents | 6 | 2026 | 225 | 1.380 |
Why?
|
| Transcatheter Aortic Valve Replacement | 5 | 2024 | 110 | 1.370 |
Why?
|
| Treatment Outcome | 29 | 2026 | 5820 | 1.350 |
Why?
|
| Angioedema | 2 | 2021 | 10 | 1.330 |
Why?
|
| Heart Valve Prosthesis Implantation | 4 | 2026 | 171 | 1.290 |
Why?
|
| Risk Factors | 26 | 2026 | 5466 | 1.280 |
Why?
|
| Adverse Drug Reaction Reporting Systems | 3 | 2024 | 48 | 1.250 |
Why?
|
| Cardiomyopathies | 4 | 2024 | 137 | 1.200 |
Why?
|
| Aged | 37 | 2026 | 15090 | 1.140 |
Why?
|
| Aortic Valve Stenosis | 4 | 2024 | 190 | 1.130 |
Why?
|
| Postoperative Complications | 3 | 2025 | 1335 | 1.120 |
Why?
|
| United States | 30 | 2026 | 8166 | 1.110 |
Why?
|
| Platelet Aggregation Inhibitors | 4 | 2023 | 235 | 1.050 |
Why?
|
| Kidney Failure, Chronic | 3 | 2023 | 197 | 1.030 |
Why?
|
| Retrospective Studies | 26 | 2026 | 6948 | 1.000 |
Why?
|
| Antihypertensive Agents | 2 | 2025 | 183 | 0.990 |
Why?
|
| Hospitalization | 19 | 2025 | 1403 | 0.980 |
Why?
|
| Hospital Mortality | 15 | 2025 | 879 | 0.940 |
Why?
|
| Tricuspid Valve Insufficiency | 1 | 2026 | 23 | 0.940 |
Why?
|
| Tricuspid Valve | 1 | 2026 | 28 | 0.940 |
Why?
|
| Conservative Treatment | 1 | 2026 | 19 | 0.930 |
Why?
|
| Stroke Volume | 7 | 2024 | 345 | 0.930 |
Why?
|
| Male | 41 | 2026 | 31297 | 0.920 |
Why?
|
| Cardiovascular Agents | 3 | 2023 | 107 | 0.920 |
Why?
|
| Denervation | 1 | 2025 | 18 | 0.900 |
Why?
|
| Female | 43 | 2026 | 34310 | 0.890 |
Why?
|
| Takotsubo Cardiomyopathy | 1 | 2026 | 69 | 0.880 |
Why?
|
| Heart-Assist Devices | 6 | 2025 | 158 | 0.870 |
Why?
|
| Heart Transplantation | 3 | 2024 | 180 | 0.860 |
Why?
|
| Obesity | 4 | 2025 | 1277 | 0.840 |
Why?
|
| Inflammatory Bowel Diseases | 1 | 2026 | 110 | 0.840 |
Why?
|
| Alopecia | 1 | 2024 | 31 | 0.840 |
Why?
|
| Anti-Arrhythmia Agents | 3 | 2025 | 102 | 0.840 |
Why?
|
| Stenosis, Pulmonary Vein | 1 | 2024 | 3 | 0.830 |
Why?
|
| Databases, Factual | 8 | 2025 | 888 | 0.830 |
Why?
|
| Bayes Theorem | 1 | 2024 | 127 | 0.820 |
Why?
|
| Coronary Occlusion | 1 | 2024 | 7 | 0.820 |
Why?
|
| Warfarin | 3 | 2023 | 125 | 0.820 |
Why?
|
| United States Food and Drug Administration | 1 | 2024 | 92 | 0.820 |
Why?
|
| Anticoagulants | 5 | 2023 | 529 | 0.810 |
Why?
|
| Length of Stay | 10 | 2025 | 828 | 0.800 |
Why?
|
| Amiodarone | 1 | 2023 | 22 | 0.790 |
Why?
|
| Recovery of Function | 2 | 2025 | 292 | 0.790 |
Why?
|
| Ductus Arteriosus, Patent | 1 | 2023 | 13 | 0.780 |
Why?
|
| Middle Aged | 31 | 2026 | 18440 | 0.770 |
Why?
|
| Health Care Costs | 2 | 2022 | 224 | 0.770 |
Why?
|
| Defibrillators, Implantable | 3 | 2022 | 273 | 0.760 |
Why?
|
| Renal Dialysis | 2 | 2023 | 191 | 0.750 |
Why?
|
| Amyloid Neuropathies, Familial | 1 | 2023 | 20 | 0.750 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2023 | 152 | 0.740 |
Why?
|
| Neoplasms | 9 | 2025 | 1376 | 0.740 |
Why?
|
| Adult | 30 | 2026 | 17511 | 0.730 |
Why?
|
| Extracorporeal Membrane Oxygenation | 1 | 2023 | 66 | 0.730 |
Why?
|
| Out-of-Hospital Cardiac Arrest | 1 | 2023 | 61 | 0.730 |
Why?
|
| Suicide | 1 | 2024 | 147 | 0.730 |
Why?
|
| Heart Valve Diseases | 1 | 2023 | 94 | 0.730 |
Why?
|
| Drug-Eluting Stents | 1 | 2023 | 68 | 0.720 |
Why?
|
| Cardiopulmonary Resuscitation | 1 | 2023 | 99 | 0.720 |
Why?
|
| Mortality, Premature | 1 | 2021 | 7 | 0.710 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2023 | 182 | 0.710 |
Why?
|
| Thrombectomy | 1 | 2024 | 263 | 0.700 |
Why?
|
| Inpatients | 9 | 2024 | 322 | 0.700 |
Why?
|
| Hyperkalemia | 1 | 2021 | 20 | 0.680 |
Why?
|
| Medicare | 2 | 2023 | 629 | 0.670 |
Why?
|
| Hypotension | 1 | 2021 | 51 | 0.660 |
Why?
|
| Peripheral Arterial Disease | 1 | 2023 | 165 | 0.650 |
Why?
|
| Shock, Cardiogenic | 4 | 2025 | 108 | 0.640 |
Why?
|
| Tachycardia, Ventricular | 1 | 2022 | 131 | 0.630 |
Why?
|
| Cardiovascular System | 1 | 2020 | 41 | 0.630 |
Why?
|
| Secondary Prevention | 1 | 2019 | 165 | 0.570 |
Why?
|
| Dementia | 1 | 2022 | 285 | 0.560 |
Why?
|
| Aged, 80 and over | 10 | 2025 | 5657 | 0.550 |
Why?
|
| Cardiomyopathy, Hypertrophic | 2 | 2024 | 801 | 0.530 |
Why?
|
| Young Adult | 10 | 2025 | 4855 | 0.500 |
Why?
|
| Cardiotoxicity | 4 | 2025 | 18 | 0.490 |
Why?
|
| Atrial Appendage | 3 | 2022 | 41 | 0.490 |
Why?
|
| Time Factors | 8 | 2025 | 3777 | 0.490 |
Why?
|
| Observational Studies as Topic | 3 | 2026 | 72 | 0.470 |
Why?
|
| Brain Ischemia | 1 | 2019 | 420 | 0.450 |
Why?
|
| Water Pollutants, Chemical | 2 | 2025 | 43 | 0.430 |
Why?
|
| Diabetic Retinopathy | 2 | 2026 | 60 | 0.430 |
Why?
|
| Adolescent | 9 | 2025 | 6350 | 0.400 |
Why?
|
| Drug Combinations | 3 | 2023 | 167 | 0.370 |
Why?
|
| Pandemics | 5 | 2023 | 691 | 0.360 |
Why?
|
| Embolism, Paradoxical | 1 | 2012 | 14 | 0.360 |
Why?
|
| Myocarditis | 3 | 2024 | 68 | 0.360 |
Why?
|
| Foramen Ovale, Patent | 1 | 2012 | 12 | 0.360 |
Why?
|
| Cardiac Catheterization | 5 | 2026 | 293 | 0.350 |
Why?
|
| Mitral Valve Insufficiency | 2 | 2024 | 98 | 0.350 |
Why?
|
| Ischemic Attack, Transient | 1 | 2012 | 96 | 0.340 |
Why?
|
| Hospitals | 6 | 2024 | 398 | 0.340 |
Why?
|
| Aminobutyrates | 2 | 2021 | 9 | 0.340 |
Why?
|
| Valsartan | 2 | 2021 | 12 | 0.340 |
Why?
|
| Tetrazoles | 2 | 2021 | 22 | 0.330 |
Why?
|
| Biphenyl Compounds | 2 | 2021 | 30 | 0.330 |
Why?
|
| Angiotensin Receptor Antagonists | 2 | 2021 | 63 | 0.320 |
Why?
|
| Aortic Valve | 4 | 2024 | 181 | 0.310 |
Why?
|
| Mortality | 3 | 2025 | 162 | 0.300 |
Why?
|
| Risk Assessment | 6 | 2025 | 2113 | 0.290 |
Why?
|
| Acute Kidney Injury | 2 | 2021 | 142 | 0.290 |
Why?
|
| Ritonavir | 3 | 2023 | 15 | 0.290 |
Why?
|
| Atherosclerosis | 2 | 2021 | 162 | 0.290 |
Why?
|
| Hypertension | 2 | 2024 | 616 | 0.280 |
Why?
|
| Prevalence | 4 | 2025 | 1453 | 0.280 |
Why?
|
| Sex Factors | 3 | 2026 | 995 | 0.280 |
Why?
|
| Hemorrhage | 3 | 2024 | 286 | 0.260 |
Why?
|
| Recombinant Fusion Proteins | 2 | 2026 | 503 | 0.260 |
Why?
|
| Coronary Angiography | 3 | 2023 | 212 | 0.250 |
Why?
|
| Propensity Score | 2 | 2024 | 192 | 0.240 |
Why?
|
| Diabetic Angiopathies | 1 | 2026 | 29 | 0.240 |
Why?
|
| Follow-Up Studies | 3 | 2026 | 2496 | 0.240 |
Why?
|
| Child | 3 | 2024 | 4634 | 0.230 |
Why?
|
| Optic Neuropathy, Ischemic | 1 | 2025 | 6 | 0.230 |
Why?
|
| Seawater | 1 | 2025 | 10 | 0.230 |
Why?
|
| Femoral Artery | 2 | 2023 | 104 | 0.230 |
Why?
|
| Blood Pressure | 2 | 2025 | 535 | 0.230 |
Why?
|
| Incretins | 1 | 2025 | 8 | 0.230 |
Why?
|
| Mitral Valve | 2 | 2023 | 126 | 0.220 |
Why?
|
| Ventricular Function, Left | 2 | 2024 | 284 | 0.220 |
Why?
|
| Hypertension, Pulmonary | 1 | 2026 | 100 | 0.210 |
Why?
|
| Diabetes Mellitus | 2 | 2025 | 555 | 0.210 |
Why?
|
| Coronary Vessel Anomalies | 1 | 2024 | 23 | 0.210 |
Why?
|
| Dipeptidyl-Peptidase IV Inhibitors | 1 | 2024 | 15 | 0.210 |
Why?
|
| Canagliflozin | 1 | 2024 | 6 | 0.210 |
Why?
|
| Glucosides | 1 | 2024 | 15 | 0.210 |
Why?
|
| Pregnancy Complications, Cardiovascular | 1 | 2024 | 38 | 0.210 |
Why?
|
| Perioperative Care | 1 | 2025 | 87 | 0.210 |
Why?
|
| Vascular Diseases | 1 | 2024 | 83 | 0.200 |
Why?
|
| Meta-Analysis as Topic | 1 | 2024 | 78 | 0.200 |
Why?
|
| Nervous System Diseases | 1 | 2025 | 108 | 0.200 |
Why?
|
| Furosemide | 1 | 2023 | 19 | 0.200 |
Why?
|
| Benzhydryl Compounds | 1 | 2024 | 61 | 0.200 |
Why?
|
| Ibuprofen | 1 | 2023 | 17 | 0.200 |
Why?
|
| Indomethacin | 1 | 2023 | 23 | 0.200 |
Why?
|
| Factor Xa Inhibitors | 1 | 2023 | 38 | 0.200 |
Why?
|
| Watchful Waiting | 1 | 2023 | 33 | 0.200 |
Why?
|
| Pyridones | 1 | 2023 | 42 | 0.200 |
Why?
|
| Infant, Low Birth Weight | 1 | 2023 | 59 | 0.190 |
Why?
|
| Benzoxazoles | 1 | 2023 | 7 | 0.190 |
Why?
|
| Health Status Disparities | 1 | 2024 | 147 | 0.190 |
Why?
|
| Environmental Exposure | 1 | 2025 | 226 | 0.190 |
Why?
|
| Popliteal Artery | 1 | 2023 | 24 | 0.190 |
Why?
|
| Prealbumin | 1 | 2023 | 21 | 0.190 |
Why?
|
| Prasugrel Hydrochloride | 1 | 2023 | 13 | 0.190 |
Why?
|
| Purinergic P2Y Receptor Antagonists | 1 | 2023 | 15 | 0.190 |
Why?
|
| Rural Population | 2 | 2022 | 224 | 0.190 |
Why?
|
| Pyrazoles | 1 | 2023 | 88 | 0.190 |
Why?
|
| Adenosine Diphosphate | 1 | 2023 | 44 | 0.190 |
Why?
|
| Disability Evaluation | 1 | 2024 | 216 | 0.190 |
Why?
|
| Catheterization, Peripheral | 1 | 2023 | 51 | 0.190 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2024 | 142 | 0.190 |
Why?
|
| Time-to-Treatment | 1 | 2024 | 133 | 0.190 |
Why?
|
| Vascular Patency | 1 | 2023 | 135 | 0.190 |
Why?
|
| Paclitaxel | 1 | 2023 | 102 | 0.180 |
Why?
|
| Climate Change | 1 | 2022 | 27 | 0.180 |
Why?
|
| Patient Readmission | 2 | 2024 | 452 | 0.180 |
Why?
|
| Administration, Oral | 1 | 2023 | 371 | 0.180 |
Why?
|
| Immunotherapy | 1 | 2025 | 274 | 0.180 |
Why?
|
| Reoperation | 1 | 2023 | 307 | 0.180 |
Why?
|
| Overweight | 1 | 2024 | 254 | 0.180 |
Why?
|
| Regression Analysis | 1 | 2023 | 498 | 0.180 |
Why?
|
| Drug Therapy, Combination | 1 | 2023 | 463 | 0.180 |
Why?
|
| Infant, Newborn | 2 | 2024 | 1437 | 0.180 |
Why?
|
| Diabetes, Gestational | 1 | 2024 | 142 | 0.170 |
Why?
|
| Arthritis, Psoriatic | 1 | 2022 | 32 | 0.170 |
Why?
|
| Ultrasonography, Interventional | 1 | 2023 | 124 | 0.170 |
Why?
|
| Death, Sudden, Cardiac | 2 | 2022 | 367 | 0.170 |
Why?
|
| Myocardial Ischemia | 1 | 2022 | 121 | 0.170 |
Why?
|
| Sex Characteristics | 1 | 2023 | 214 | 0.170 |
Why?
|
| Algorithms | 2 | 2024 | 1052 | 0.170 |
Why?
|
| Clinical Trials as Topic | 1 | 2024 | 462 | 0.170 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2023 | 214 | 0.170 |
Why?
|
| Infant, Premature | 1 | 2023 | 199 | 0.170 |
Why?
|
| Septal Occluder Device | 1 | 2021 | 11 | 0.170 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2021 | 47 | 0.170 |
Why?
|
| Longitudinal Studies | 1 | 2025 | 1288 | 0.170 |
Why?
|
| Giant Cells | 1 | 2021 | 16 | 0.170 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2022 | 162 | 0.170 |
Why?
|
| Population Surveillance | 1 | 2022 | 210 | 0.170 |
Why?
|
| Chronic Disease | 1 | 2024 | 744 | 0.160 |
Why?
|
| Intracranial Hemorrhages | 1 | 2021 | 71 | 0.160 |
Why?
|
| Pulmonary Embolism | 1 | 2023 | 198 | 0.160 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2021 | 139 | 0.160 |
Why?
|
| Periodontal Diseases | 1 | 2020 | 17 | 0.160 |
Why?
|
| Cardiology | 1 | 2022 | 170 | 0.160 |
Why?
|
| Anemia | 1 | 2021 | 132 | 0.160 |
Why?
|
| Multimodal Imaging | 1 | 2020 | 72 | 0.160 |
Why?
|
| Prostatic Neoplasms | 1 | 2024 | 501 | 0.150 |
Why?
|
| Asthma | 1 | 2023 | 485 | 0.140 |
Why?
|
| Prospective Studies | 2 | 2023 | 3329 | 0.140 |
Why?
|
| Delivery of Health Care | 1 | 2022 | 439 | 0.140 |
Why?
|
| Antineoplastic Agents | 1 | 2023 | 644 | 0.140 |
Why?
|
| Betacoronavirus | 1 | 2020 | 181 | 0.140 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 205 | 0.130 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 219 | 0.130 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2023 | 707 | 0.130 |
Why?
|
| Breast Neoplasms | 1 | 2024 | 1233 | 0.110 |
Why?
|
| Comorbidity | 3 | 2023 | 1120 | 0.110 |
Why?
|
| Quality of Life | 1 | 2022 | 1265 | 0.110 |
Why?
|
| Cohort Studies | 3 | 2026 | 2639 | 0.100 |
Why?
|
| Coronary Disease | 2 | 2012 | 246 | 0.090 |
Why?
|
| Myocardial Perfusion Imaging | 1 | 2012 | 53 | 0.090 |
Why?
|
| Cross-Sectional Studies | 3 | 2025 | 2730 | 0.090 |
Why?
|
| Incidence | 2 | 2026 | 1432 | 0.080 |
Why?
|
| Lipoproteins, LDL | 1 | 2010 | 48 | 0.080 |
Why?
|
| Pregnancy | 2 | 2024 | 2393 | 0.060 |
Why?
|
| Liraglutide | 1 | 2026 | 8 | 0.060 |
Why?
|
| Glucagon-Like Peptides | 1 | 2026 | 8 | 0.060 |
Why?
|
| Glucagon-Like Peptide 1 | 1 | 2026 | 30 | 0.060 |
Why?
|
| Immunoglobulin Fc Fragments | 1 | 2026 | 50 | 0.060 |
Why?
|
| Glucagon-Like Peptide-1 Receptor | 1 | 2025 | 15 | 0.060 |
Why?
|
| Cause of Death | 1 | 2026 | 221 | 0.060 |
Why?
|
| Datasets as Topic | 1 | 2025 | 29 | 0.050 |
Why?
|
| Mobility Limitation | 1 | 2025 | 49 | 0.050 |
Why?
|
| Renin-Angiotensin System | 1 | 2024 | 22 | 0.050 |
Why?
|
| Androgen Antagonists | 1 | 2024 | 32 | 0.050 |
Why?
|
| Proportional Hazards Models | 1 | 2026 | 746 | 0.050 |
Why?
|
| Peripartum Period | 1 | 2024 | 17 | 0.050 |
Why?
|
| Delivery, Obstetric | 1 | 2024 | 62 | 0.050 |
Why?
|
| Lactams | 1 | 2023 | 21 | 0.050 |
Why?
|
| Sodium-Glucose Transporter 2 | 1 | 2023 | 6 | 0.050 |
Why?
|
| Proline | 1 | 2023 | 46 | 0.050 |
Why?
|
| Hemodynamics | 1 | 2025 | 252 | 0.050 |
Why?
|
| Spasm | 1 | 2023 | 10 | 0.050 |
Why?
|
| Anthracyclines | 1 | 2023 | 11 | 0.050 |
Why?
|
| Leucine | 1 | 2023 | 65 | 0.050 |
Why?
|
| Nitriles | 1 | 2023 | 82 | 0.050 |
Why?
|
| Ulnar Artery | 1 | 2023 | 12 | 0.050 |
Why?
|
| Heart Rate | 1 | 2025 | 334 | 0.050 |
Why?
|
| Diuretics | 1 | 2023 | 58 | 0.050 |
Why?
|
| Blood Glucose | 1 | 2026 | 502 | 0.050 |
Why?
|
| Recurrence | 1 | 2025 | 664 | 0.050 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2024 | 105 | 0.050 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2023 | 38 | 0.050 |
Why?
|
| Hospitals, Teaching | 1 | 2023 | 105 | 0.050 |
Why?
|
| Pregnancy Outcome | 1 | 2024 | 202 | 0.050 |
Why?
|
| Hematoma | 1 | 2023 | 85 | 0.050 |
Why?
|
| Radial Artery | 1 | 2023 | 55 | 0.050 |
Why?
|
| Coronary Vessels | 1 | 2023 | 125 | 0.050 |
Why?
|
| Sulfonamides | 1 | 2023 | 134 | 0.050 |
Why?
|
| Drug Interactions | 1 | 2022 | 126 | 0.050 |
Why?
|
| Hospitals, Community | 1 | 2022 | 73 | 0.050 |
Why?
|
| Behavioral Risk Factor Surveillance System | 1 | 2022 | 45 | 0.040 |
Why?
|
| Medical Oncology | 1 | 2022 | 70 | 0.040 |
Why?
|
| New Mexico | 1 | 2021 | 9 | 0.040 |
Why?
|
| Arizona | 1 | 2021 | 13 | 0.040 |
Why?
|
| Mexico | 1 | 2021 | 39 | 0.040 |
Why?
|
| Texas | 1 | 2021 | 60 | 0.040 |
Why?
|
| Electric Countershock | 1 | 2022 | 109 | 0.040 |
Why?
|
| Endocardium | 1 | 2021 | 14 | 0.040 |
Why?
|
| Troponin I | 1 | 2021 | 36 | 0.040 |
Why?
|
| Fibrinolytic Agents | 1 | 2022 | 183 | 0.040 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2023 | 377 | 0.040 |
Why?
|
| California | 1 | 2021 | 178 | 0.040 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2021 | 58 | 0.040 |
Why?
|
| Sex Distribution | 1 | 2021 | 252 | 0.040 |
Why?
|
| Niacinamide | 1 | 2020 | 33 | 0.040 |
Why?
|
| Antiviral Agents | 1 | 2023 | 330 | 0.040 |
Why?
|
| Age Distribution | 1 | 2021 | 262 | 0.040 |
Why?
|
| Registries | 1 | 2025 | 934 | 0.040 |
Why?
|
| History, 21st Century | 1 | 2021 | 180 | 0.040 |
Why?
|
| Oxygen | 1 | 2022 | 321 | 0.040 |
Why?
|
| Survival Analysis | 1 | 2021 | 579 | 0.040 |
Why?
|
| Kidney | 1 | 2022 | 458 | 0.040 |
Why?
|
| Biopsy | 1 | 2021 | 460 | 0.040 |
Why?
|
| Echocardiography | 1 | 2022 | 513 | 0.040 |
Why?
|
| Immunosuppressive Agents | 1 | 2021 | 381 | 0.040 |
Why?
|
| Heart | 1 | 2021 | 298 | 0.040 |
Why?
|
| Pilot Projects | 1 | 2022 | 1026 | 0.040 |
Why?
|
| Quality Improvement | 1 | 2022 | 468 | 0.030 |
Why?
|
| Electrocardiography | 1 | 2021 | 555 | 0.030 |
Why?
|
| Body Mass Index | 1 | 2021 | 900 | 0.030 |
Why?
|
| Health Services Accessibility | 1 | 2022 | 603 | 0.030 |
Why?
|
| Child, Preschool | 1 | 2022 | 2076 | 0.030 |
Why?
|
| Biomarkers | 1 | 2021 | 1487 | 0.030 |
Why?
|
| Inflammation | 1 | 2020 | 1195 | 0.020 |
Why?
|
| Diabetes Complications | 1 | 2012 | 106 | 0.020 |
Why?
|
| Anticholesteremic Agents | 1 | 2010 | 35 | 0.020 |
Why?
|
| Demography | 1 | 2010 | 178 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2012 | 1144 | 0.020 |
Why?
|